ADAG
Adagene Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Adagene has 2 disclosed suppliers and 5 disclosed customers in SEC filings.
—
—
SentenceIn July 2021, we entered into clinical collaboration with Merck, a leader in immuno-oncology. The clinical collaboration and supply agreement includes open-label, dose escalation and expansion clinical studies to evaluate our anti-CTLA-4 mAb product candidate, ADG126 in combination with pembrolizumab for patients with advanced/metastatic solid tumors. Under terms of the agreement, Merck provides pembrolizumab and input on our clinical trials evaluating pembrolizumab in combination with ADG126
SentenceIn December 2022, we announced a clinical trial collaboration agreement with Roche to evaluate the triple combination of our ADG126 with Roche's atezolizumab and bevacizumab in first-line treatment of advanced hepatocellular carcinoma (HCC).
ADAG 20-Faccession 0001104659-26-038612
SentenceOur technology licensing agreements with Sanofi and Exelixis focus on developing antibody-based therapeutics against tumor targets using our SAFEbody technology. In 2025 - Sanofi exercised its option for a third SAFEbody discovery program, building on the 2022 collaboration.
SentenceWe collaborated with ConjugateBio on bispecific ADCs using Adagene-derived antibody, further demonstrating scalable platform potential.
ADAG 20-Faccession 0001104659-26-038612
SentenceWe have out-licensed the Greater China rights for two antibody candidates to Sanjin and its affiliates.
ADAG 20-Faccession 0001104659-26-038612
SentenceWe partnered with Third Arc Bio to develop two masked CD3 T cell engagers, expanding SAFEbody into next-generation T cell therapies.
ADAG 20-Faccession 0001104659-26-038612
Adagene Inc.
2.52
Linked news
Expected move
No implied move.